CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Palonosetron +2 moredrug
Likely dose
Palonosetron 0.25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00600353
NCT00600353Phase 2Completed
CompareCT.gov

Combined Use of Multi-Day Doses of Palonosetron and Aprepitant With Low Doses Dexamethasone in Prevention of Nausea and Emesis Among Patients With Multiple Myeloma and Lymphoma Undergoing Autologous Stem Cell Transplant: A Pilot Study

University of Kansas Medical Center·interventional·Posted Jan 25, 2008·Updated Mar 9, 2017

In Brief

A Phase 2 clinical trial evaluating Palonosetron, Aprepitant, and 1 other intervention for Myeloma, Plasma-Cell and Lymphoma, Malignant. Completed, enrolled 20 participants across 1 site.

Detailed Summary

To assess emetic responses to multi-day doses of Palonosetron and Aprepitant and low dose dexamethasone +/- Prochlorperazine among patients with multiple myeloma and lymphoma undergoing autologous HSCT utilizing the Multinational Association for Supportive Care in Cancer (MASCC) Antiemesis Tool (MAT).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyeloma, Plasma-Cell, Lymphoma, Malignant
CountriesUnited States
CollaboratorsEisai Inc.

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 25, 2008
Enrollment StartOct 1, 2007
Primary CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 18.4 years ago

Interventions

Palonosetrondrug

Palonosetron 0.25 mg IV over 30 seconds

Aprepitantdrug

Aprepitant 125 mg PO and Aprepitant 80 mg PO

Dexamethasonedrug

Dexamethasone 4 mg IV and Dexamethasone 4 mg IV push